A Cohort Study of Uterine Malignancies

NCT ID: NCT05635123

Last Updated: 2025-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

6200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-15

Study Completion Date

2030-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purposes of current study were to explore the relationship between cervical cancer/endometrial cancer and demographic information, behavior and life style, pregnancy-related factors, and disease history, and to study the factors affecting the prognosis of cancers. In addition, omics tests were performed on the biological specimens to identify the diagnostic markers and prognostic biomarkers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After being informed about the study and potential risks, all patients who meet the eligibility requirements will be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer Endometrial Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

This is a prospective observational study with no intervention.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 20-75 years;
* Women with cervical cancer or endometrial cancer with a definite pathological diagnosis for the first time;
* Women attending a health check-up;
* Obtain informed consent and sign an informed consent form.

Exclusion Criteria

* Patients who are unable to cooperate with the investigations such as mental disorders or cognitive impairment;
* Patients with cancer other than cervical cancer or endometrial cancer;
* Women who have received hysterectomy or pelvic radiation therapy previously.
Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Women's Hospital School Of Medicine Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hui Wang, PhD

Role: PRINCIPAL_INVESTIGATOR

Women's Hospital School Of Medicine Zhejiang University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Women's hospital school of medicine zhejiang university

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hui Wang, PhD

Role: CONTACT

0571-89998857

Xiao Li, PhD

Role: CONTACT

13958160137

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hui Wang, PhD

Role: primary

057189998857

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-20220352-R

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.